Aniling completes the Retos Colaboración project with the development of a genetic and epigenetic test (GEUS-LB®) for the early detection of colorectal cancer in a blood sample. The Aniling -led project uses patented GEUS …
The health biotechnology magazine Farmabiotec reports on Aniling’s late achivements. Farmabiotec goes through Aniling’s IVD tests for chronic lymphocytic leukaemia, colorectal cancer and liquid biopsy and highlights their recent CE …
Expansión newspaper explains the company’s latest milestone: Aniling obtains CE marking for three in vitro tests for chronic lymphocytic leukaemia, colorectal cancer and liquid biopsy. News written by Gabriel Trindade …
Aniling has attended “The Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology” organized by the Cell Press and the National Cancer Institute (NCI). Sheila Santín has presented the advances of …
Aniling has attended to the International Workshop of Chronic Lymphocytic Leukemia (iwCLL2021), the biennial international meeting committed to advancing the field of CLL. Ester Cuenca has presented the advances of …
We are very proud to announce that Aniling has reached the CE Mark for our first product, GEUS-CLL, a first-in-class IVD medical device to support the diagnosis, prognosis, treatment selection …
Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring. At Aniling, we have developed a new product, GEUS-LB, targeting …
Thanks to the brilliant Aniling teamwork and the invaluable guidance of Ambit BST, we are happy to announce that Aniling has succeeded in the two stages of audits to achieve the ISO 13485:2016. It has been …
